This study is testing a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA Nephropathy (IgAN), a kidney disease. Researchers want to understand changes in the disease and how sibeprenlimab might help. You could be eligible if you are at least 16 years old, have a confirmed diagnosis of IgAN from a kidney biopsy, and your kidney function (eGFR) is above 45 mL/min/1.73 m2. The main goal is to measure how much IgA (a type of protein) deposits in your kidney tissue changes after treatment with sibeprenlimab over 52 weeks. The current status of this study is unclear, and it plans to enroll 25 participants.

Study design

This is an open-label, Phase 2b study, meaning both you and the study team will know you are receiving sibeprenlimab. It plans to enroll 25 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured up to Week 52, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.